Kairos Pharma, Ltd. (KAPA)

US · Healthcare · Biotechnology

$0.33+4.90%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-1.7M

Profit YoY

-31.1%

EPS

$-0.08

EPS estimate

$-0.07

EPS came in at -0.08 against a street estimate of -0.07 — a miss of 14.3%.

Market cap

$6.6M

Forward P/E

0.0

P/B

1.23

Book value

$0.25

EPS (TTM)

$-0.30

52-week high

$2.11

52-week low

$0.27

50-day MA

$0.40

200-day MA

$0.65

Analysts rate Kairos Pharma, Ltd. a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $7.00.

Insiders

37.20%

Institutions

6.94%

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Kairos Pharma, Ltd. — free to start.

Data updated 2026-08-05.